Cargando…

Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression

Depressed individuals who carry the short allele for the serotonin-transporter-linked promotor region of the gene are more vulnerable to stress and have reduced response to first-line antidepressants such as selective serotonin reuptake inhibitors. Since depression severity has been reported to corr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uzungil, Volkan, Tran, Harvey, Aitken, Connor, Wilson, Carey, Opazo, Carlos M., Li, Shanshan, Payet, Jennyfer M., Mawal, Celeste H., Bush, Ashley I., Hale, Matthew W., Hannan, Anthony J., Renoir, Thibault
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606181/ https://www.ncbi.nlm.nih.gov/pubmed/35861925 http://dx.doi.org/10.1007/s13311-022-01257-0

Ejemplares similares

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
por: Kim, Choon-Mee, et al.
Publicado: (2009)

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients
por: Won, Sung Chul, et al.
Publicado: (2010)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE
por: Tran, Ngan Thi, et al.
Publicado: (2022)

Microbiome Profiling Reveals Gut Dysbiosis in the Metabotropic Glutamate Receptor 5 Knockout Mouse Model of Schizophrenia
por: Gubert, Carolina, et al.
Publicado: (2020)

Salmonella Typhimurium and Pseudomonas aeruginosa Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
por: Ammendola, Serena, et al.
Publicado: (2021)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
Publicado: (2019)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy
por: Salehi, Samie, et al.
Publicado: (2017)

Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy
por: Romano, Nicola, et al.
Publicado: (2022)

Deferiprone−Resveratrol Hybrid, an Iron-Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in Plasmodium berghei-Infected Mice
por: Chuljerm, Hataichanok, et al.
Publicado: (2022)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Group I Metabotropic Glutamate Receptors Modulate Motility and Enteric Neural Activity in the Mouse Colon
por: Leembruggen, Anita J. L., et al.
Publicado: (2023)

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
por: Martin-Bastida, Antonio, et al.
Publicado: (2017)

Quantum chemical analysis of the deferiprone–iron binding reaction
por: Wiwanitkit, Viroj
Publicado: (2006)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved
por: Renoir, Thibault
Publicado: (2013)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia
por: Schmidt, Paul J, et al.
Publicado: (2015)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone
por: Timoshnikov, Viktor A., et al.
Publicado: (2020)

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Iron-loaded deferiprone can support full hemoglobinization of cultured red blood cells
por: Gallego-Murillo, Joan Sebastián, et al.
Publicado: (2023)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Phosphoproteomic dysregulation in Huntington’s disease mice is rescued by environmental enrichment
por: Mees, Isaline, et al.
Publicado: (2022)

Alterations in iron content, iron-regulatory proteins and behaviour without tau pathology at one year following repetitive mild traumatic brain injury
por: Juan, Sydney M. A., et al.
Publicado: (2023)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone
por: Wang, Chong, et al.
Publicado: (2023)

Hippocampal Neurogenesis, Cognitive Deficits and Affective Disorder in Huntington's Disease
por: Ransome, Mark I., et al.
Publicado: (2012)

Topical Iron Chelator Therapy: Current Status and Future Prospects
por: Ramadoss, Tanya, et al.
Publicado: (2023)

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Iron Chelation in Local Infection
por: Scott, Cassidy, et al.
Publicado: (2021)

Role of Iron Chelators in Mucormycosis
por: Mahalmani, Vidya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_snq0c1kr18c02c8n0c9dvs1qu6